Toprak, S. K. Et Al. 2004. Both Higher Level of (bcr,abl) Transcripts and High Hasford Risk Score Are Associated with Cytogenetic Response but Absence of Molecular Remission during First Line Use of Imatinib Mesilate(IM): A Finding Not Observed Following Use among Interferon Failures.. BLOOD , vol.104, no.11 , 4671.

Toprak, S. K., Dalva, K., Mizrak, D., Arat, M., Ozcan, M., Gurman, G., ... Ilhan, O.(2004). Both Higher Level of (bcr,abl) Transcripts and High Hasford Risk Score Are Associated with Cytogenetic Response but Absence of Molecular Remission during First Line Use of Imatinib Mesilate(IM): A Finding Not Observed Following Use among Interferon Failures.. BLOOD , vol.104, no.11, 4671.

Toprak, Selami Et Al. "Both Higher Level of (bcr,abl) Transcripts and High Hasford Risk Score Are Associated with Cytogenetic Response but Absence of Molecular Remission during First Line Use of Imatinib Mesilate(IM): A Finding Not Observed Following Use among Interferon Failures.," BLOOD , vol.104, no.11, 4671, 2004

Toprak, Selami K. Et Al. "Both Higher Level of (bcr,abl) Transcripts and High Hasford Risk Score Are Associated with Cytogenetic Response but Absence of Molecular Remission during First Line Use of Imatinib Mesilate(IM): A Finding Not Observed Following Use among Interferon Failures.." BLOOD , vol.104, no.11, pp.4671, 2004

Toprak, S. K. Et Al. (2004) . "Both Higher Level of (bcr,abl) Transcripts and High Hasford Risk Score Are Associated with Cytogenetic Response but Absence of Molecular Remission during First Line Use of Imatinib Mesilate(IM): A Finding Not Observed Following Use among Interferon Failures.." BLOOD , vol.104, no.11, p.4671.

@article{article, author={Selami K. Toprak Et Al. }, title={Both Higher Level of (bcr,abl) Transcripts and High Hasford Risk Score Are Associated with Cytogenetic Response but Absence of Molecular Remission during First Line Use of Imatinib Mesilate(IM): A Finding Not Observed Following Use among Interferon Failures.}, journal={BLOOD}, year=2004, pages={4671} }